Atopic dermatitis (AD) or atopic eczema is a very common skin condition due to skin inflammation. It is usually a long-term condition where the skin becomes itchy, dry, cracked, sore and red. About one in every five children in the UK have AD. This condition may have impacts on the affected child’s quality of life. AD cannot be cured although it can improve significantly, or even clear completely, in some children as they get older. There is an unmet need for safe and effective long-term treatment for moderate-to-severe AD particularly in children.
Dupilumab is a monoclonal antibody medicine that is currently in development as an injection under the skin (subcutaneous) for the treatment of moderate to severe AD in children. Dupilumab is already licensed in the UK for the treatment of moderate-to-severe atopic dermatitis in adults. If licensed, dupilumab will offer an additional treatment option for children aged 12 years to 17 years with moderate to severe atopic dermatitis uncontrolled on current therapies.
Secukinumab as a subcutaneous injection is in clinical development for the treatment of enthesitis related arthritis (ERA) and juvenile psoriatic arthritis (JPsA). These conditions belong to a group of arthritis conditions of unknown cause known as juvenile idiopathic arthritis which affect children. JPsA patients have arthritis and psoriasis, an inflammatory skin disease and ERA patients have arthritis and enthesitis, inflammation of the ligaments and tendons. These conditions are the result of the immune system mistakenly attacking the body’s own cells at the joints and the skin or tendons, causing swelling, pain and reduced mobility.